Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BTAI
BTAI logo

BTAI News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BTAI News

BioXcel Submits sNDA for IGALMI® in At-Home Treatment

3d agoNewsfilter

BioXcel Therapeutics Q4 Earnings Beat Expectations

3d agoseekingalpha

BioXcel Therapeutics Enters Securities Purchase Agreement for $8 Million Offering

Mar 10 2026Newsfilter

BioXcel Therapeutics Shares Decline Despite Positive Drug Development News

Mar 06 2026Benzinga

BIOXCEL THERAPEUTICS STOCK INCREASES 2.7% FOLLOWING POSITIVE RESULTS FROM MID-STAGE TRIAL OF EXPERIMENTAL OPIOID WITHDRAWAL TREATMENT

Mar 05 2026moomoo

BioXcel Therapeutics Reports Positive Phase 2 Results for Opioid Withdrawal Treatment

Mar 05 2026Benzinga

BioXcel Therapeutics Reports Positive Phase 2 Trial Results for Opioid Withdrawal Treatment

Mar 05 2026stocktwits

Halper Sadeh Investigates BioXcel Therapeutics for Potential Breach of Fiduciary Duties

Jan 15 2026Businesswire

BTAI Events

03/27 09:00
Stock Futures Modestly Lower as Energy Prices Rise
Stock futures are modestly lower ahead of the open, indicating a weaker start. The move follows another sharp decline in the prior session, where the S&P 500 fell more than 1% and the Nasdaq dropped over 2%, moving into correction territory.The primary driver remains energy. Oil prices are rising again, with Brent crude trading above $110 per barrel. Although prices are on track for a slight weekly decline, they remain significantly elevated due to ongoing supply disruptions tied to the Iran conflict.That persistence in elevated oil prices is continuing to feed into broader market conditions. Treasury yields are climbing, with the 10-year approaching the mid-4% range, and rate expectations have shifted meaningfully. Markets that previously anticipated rate cuts are now pricing in the possibility of further tightening, reflecting concern that the energy shock could keep inflation elevated.In pre-market trading, S&P 500 futures fell 0.45%, Nasdaq futures fell 0.67% and Dow futures fell 0.39%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -AstraZenecaup 4% after announcing tozorakimab met the primary endpoint in OBERON and TITANIA trialsUP AFTER EARNINGS -Newsmaxup 12%Arganup 10%Legenceup 9%BioXcel Therapeuticsup 3%DOWN AFTER EARNINGS -Humacytedown 7%P3 Health Partnersdown 6%Autolus Therapeuticsdown 4%Laird Superfooddown 4%LOWER -Two Harborsdown 1% after entering into a definitive merger agreement pursuant to which CrossCountry will acquire all of the outstanding shares of Two Harbors common stock for $10.80 per share in cash
03/27 07:20
BioXcel Therapeutics Q4 Revenue Reaches $256,000
Reports Q4 revenue $256,000, consensus $151,520. "2025 was a successful year for our Company, setting the stage for the potential label expansion of IGALMI in the at-home setting and continuing progress with commercial plans for the potential launch of IGALMI," said Vimal Mehta, CEO of BioXcel Therapeutics. "Our confidence in the substantial market opportunity in the at-home setting, where there are no FDA-approved options available, is reiterated by our recent market opportunity assessment. We also remain focused on advancing our Alzheimer's dementia program, which is another large market opportunity."

BTAI Monitor News

BioXcel Therapeutics rises amid sector rotation

Mar 05 2026

BTAI Earnings Analysis

No Data

No Data

People Also Watch